Impact News +++ Marvell Technology Slips 30% YTD: Should You Hold or Fold the Stock? (Zacks) +++ MARVELL Aktie -3,27%

CURIS Aktie

>CURIS Aktienkurs

1.59 EUR -12.6% (Tradegate)

Ask: 1.48 EUR / 2700 Stück

Bid: 1.46 EUR / 2750 Stück

Tagesumsatz: 1143 Stück

Realtime Kurs von 8 bis 22 Uhr!

CURIS Aktie über LYNX handeln

Intraday

1 Jahr

>CURIS Performance

1 Woche: -12,2%

1 Monat: -27,1%

3 Monate: +16,9%

6 Monate: -61,2%

1 Jahr: -77,0%

laufendes Jahr: -48,4%

>CURIS Aktie

Name:

CURIS INC. DL -,01

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US2312693094 / A3ETJD

Symbol/ Ticker:

CUS0 (Frankfurt) / CRIS (NASDAQ)

Kürzel:

FRA:CUS0, ETR:CUS0, CUS0:GR, NASDAQ:CRIS

Index:

Webseite:

https://www.curis.com/

Marktkapitalisierung:

25.18 Mio. EUR

Umsatz:

9.7 Mio. EUR

EBITDA:

-36.41 Mio. EUR

Gewinn je Aktie:

-4.574 EUR

Schulden:

29.76 Mio. EUR

Liquide Mittel:

17.57 Mio. EUR

Umsatz-/ Gewinnwachstum:

14.1% / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

1.71 / 4.27 / -

Gewinnm./ Eigenkapitalr.:

- / -2%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

CURIS

Letzte Datenerhebung:

02.07.25

>CURIS Eigentümer

Aktien: 10.46 Mio. St.

f.h. Aktien: 8.38 Mio. St.

Insider Eigner: 8.64%

Instit. Eigner: 44.65%

Leerverk. Aktien: 1.31%

>CURIS Peer Group

ADAGENE

ARMATA

CO-DIAGNOSTICS

EDAP TMS

FONAR

MIRA PHARMACEUTICALS

OMEROS

PRO-DEX

SCYNEXIS

WHITEHAWK THERAPEUTICS

>CURIS Chart & Kurs - NASDAQ

>CURIS News

02.07.25 - 14:36	Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement (PR Newswire)
	LEXINGTON, Mass., July 2, 2025 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a......

07.05.25 - 00:18	Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
	LEXINGTON, Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of Directors of Curis approved the grant of inducement......

06.05.25 - 20:45	Curis highlights progress in lymphoma and AML trials with expanded patient enrollment (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.25 - 15:33	Shawn "JAY-Z" Carter Files Amended Lawsuit in Alabama To Include Lawyer Antigone Curis As Co-Conspirator and To Reveal Tony Buzbee Edited Wikipedia Pages To Damage Carter & Roc Nation′s Reputations (PR Newswire)
	NEW YORK, May 6, 2025 /PRNewswire/ -- Today, Shawn "JAY-Z" Carter filed an amended lawsuit in Alabama that revealed that lawyer Tony Buzbee directed his employees to negatively edit Carter and his company Roc Nation's Wikipedia pages to damage their reputations. The complaint explains......

06.05.25 - 14:36	Curis Inc Q1 Loss Decreases, Beats Estimates (AFX)
	WASHINGTON (dpa-AFX) - Curis Inc (CRIS) announced Loss for first quarter that decreased from the same period last year and beat the Street estimates.The company's earnings came in at -$10.62 milli......

06.05.25 - 14:09	Curis GAAP EPS of -$1.25 misses by $0.06, revenue of $2.38M misses by $0.22M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.05.25 - 18:06	Curis Q1 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.04.25 - 22:09	Curis to Present at Upcoming Healthcare Conference in April (PR Newswire)
	LEXINGTON, Mass., April 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis,......

31.03.25 - 16:06	Curis targets accelerated approval for emavusertib in PCNSL with 12-18 month enrollment timeline (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.03.25 - 15:12	Curis Inc Q4 Loss Narrows (AFX)
	WASHINGTON (dpa-AFX) - Curis Inc (CRIS) announced Loss for fourth quarter of -$9.618 millionThe company's earnings totaled -$9.618 million, or -$1.25 per share. This compares with -$11.712 million......

31.03.25 - 14:09	Curis GAAP EPS of -$1.25, revenue of $3.35M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.03.25 - 14:03	Curis Provides Fourth Quarter 2024 Business Update (PR Newswire)
	FDA and EMA discussions completed to support a potential accelerated approval path in both US and EU Orphan Drug Designation for PCNSL granted in both US and EU Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., March 31, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:......

28.03.25 - 21:09	Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 (PR Newswire)
	LEXINGTON, Mass., March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and......

02.01.25 - 23:12	Curis Shares Gain on Results From Leukemia-Treatment Study (MarketWatch)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

14.11.24 - 16:37	Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
	Curis (CRIS) delivered earnings and revenue surprises of 9.57% and 3.20%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?...

14.11.24 - 14:37	Curis Inc Q3 Loss Decreases, Beats Estimates (AFX)
	WASHINGTON (dpa-AFX) - Curis Inc (CRIS) released Loss for third quarter that decreased from the same period last year and beat the Street estimates.The company's bottom line totaled -$10.09 millio......

14.11.24 - 14:01	Curis Provides Third Quarter 2024 Business Update (PR Newswire)
	Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported......

07.11.24 - 14:03	Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024 (PR Newswire)
	LEXINGTON, Mass., Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and......

29.10.24 - 11:30	Curis looks to raise $12.1M in private placement (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.10.24 - 11:10	Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement (PR Newswire)
	LEXINGTON, Mass., Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der guckt die Bälle weg. - Fritz Walter

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram